HIGH-NEED HEALTHCARE: New Patents to Change Medicine as We Know It!
The domain of mental health is one of the fastest-developing areas of the vast healthcare system. Massive amounts of capital are flowing in because insiders know just how lucrative breakthrough medicines can be. Through patents, first-mover status and a lasting market footprint can be established.
But patents are born of clinical research, which is the foundation of scientific progress. Unfortunately, alternative solutions for mental health issues like depression, anxiety, substance abuse, and post-traumatic stress disorder were ignored for many years. Take, for example, psychedelic medicine, a mostly unexplored and untapped resource that offers tremendous healing potential.
While the mainstream medical community ignored psychedelics in favor of medications like Valium and Prozac, a small but growing community of brave researchers have explored the viability of psilocybin and ketamine as effective treatment options.
What they’ve discovered might surprise you. For instance, researchers at Johns Hopkins University found that psilocybin, which can be derived from magic mushrooms, reduces the brain’s response to negative emotional stimuli. Post-treatment, depressed patients were reported to have newfound feelings of hope and self-worth.
Overall, the patients treated with psilocybin found that the experience was profoundly meaningful and after just one or two treatment sessions, they reported positive long-term changes in mood, attitude, and behavior. Breaking free from crippling depression would be an absolute godsend for patients who suffer from this terrible condition, and there’s now hope on the horizon.
It was also found that the psilocybin-based drug treatment was not addictive. That fact alone suggests that psychedelic options may be safer than the meds being prescribed by doctors today. After the initial trials were completed, the results were so encouraging that other universities joined Johns Hopkins in the quest to uncover the full healing potential of psychedelic medicines.
In order to increase mainstream acceptance and provide more value to investors, more research, patents, and products are needed. One company in the space, Champignon Brands (CSE: SHRM, OTC: SHRMF), has effectively covered these areas through a series of highly-strategic acquisitions.
These value-added acquisitions cover the critical-need areas of research and development, innovative delivery systems, and final products for the vast pool of consumers.
93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.
Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!
Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!
Champignon’s acquisitions so far include:
- AltMed, whose Ontario-based clinic known as the Canadian Rapid Treatment Centre of Excellence is currently the only Health Canada-approved clinic for randomized controlled trials for psilocybin
- Novo Formulations, a specialty biotechnology company focused on developing novel delivery systems for ketamine, anesthetics, adaptogenics, and more
- Tassili Life Sciences Corp., which develops therapeutics for pathological and psychological diseases based on psychedelic and cannabis compounds
- Vitality Superteas, which are formulated to revolutionize conventional organic teas through the infusion of a proprietary blend of artisanal mushrooms with medicinal properties
What’s coming down the pipeline for Champignon Brands? Very soon, the company plans to roll out five unique ketamine clinics across Florida, California, and the U.S. Eastern Seaboard. These additional ketamine clinics are projected to be fully operational by the fall of 2020.
This will mean more research and the potential for first-to-market patents and products, all thanks to the dedication and innovation you’ll only find at Champignon Brands.
Best Regards,
FutureMoneyTrends.com
Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!
Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!
Legal Notice:
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.
Never base any decision off of our emails. CrushTheStreet.com stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Future Money Trends LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please review our entire disclaimer at FutureMoneyTrends.com/disclaimer.
